An investigational trial comparing the efficacy and safety of once weekly NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in combination with metformin, with or without DPP-4 inhibitors, in insulin naïve subjects with type 2 diabetes mellitus
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2019
At a glance
- Drugs Insulin 287 (Primary) ; Insulin glargine
- Indications Diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 29 Nov 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2018 Status changed from planning to recruiting.
- 17 Aug 2018 New trial record